Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| DC-AHS-0006 | |||
| SMART |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the effects of high doses of candesartan cilexetil and also to assess which dose (16mg, 64mg, 128mg) is the most optimal for the maximum reduction of proteinuria.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| candesartan cilexetil | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| To determine the effects of high dose candesartan cilexetil on the overall reduction in proteinuria from baseline as evidenced by the 24-hour urine collection |
| Measure | Description | Time Frame |
|---|---|---|
| To determine the effects of high dose candesartan cilexetil on renal function as measured by serum creatinine and 24-hour creatinine clearance | ||
| To determine the effects of high dose candesartan cilexetil on blood pressure |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kazi Borkowski, PhD | AstraZeneca | Study Director |
| Norman MuirHead, MD | London HSC | Principal Investigator |
| Ellen Burgess, MD | Foothills Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Calgary | Alberta | Canada | |||
| Research Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38682786 | Derived | Natale P, Palmer SC, Navaneethan SD, Craig JC, Strippoli GF. Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2024 Apr 29;4(4):CD006257. doi: 10.1002/14651858.CD006257.pub2. | |
| 37466151 | Derived | Cooper TE, Teng C, Tunnicliffe DJ, Cashmore BA, Strippoli GF. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD007751. doi: 10.1002/14651858.CD007751.pub3. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Edmonton |
| Alberta |
| Canada |
| Research Site | Kelowna | British Columbia | Canada |
| Research Site | Vancouver | British Columbia | Canada |
| Research Site | Winnipeg | Manitoba | Canada |
| Research Site | St. John's | Newfoundland and Labrador | Canada |
| Research Site | Halifax | Nova Scotia | Canada |
| Research Site | Courtice | Ontario | Canada |
| Research Site | Greater Sudbury | Ontario | Canada |
| Research Site | Kitchener | Ontario | Canada |
| Research Site | London | Ontario | Canada |
| Research Site | Mississauga | Ontario | Canada |
| Research Site | Oakville | Ontario | Canada |
| Research Site | Oshawa | Ontario | Canada |
| Research Site | Richmond Hill | Ontario | Canada |
| Research Site | Scarborough Village | Ontario | Canada |
| Research Site | Thunder Bay | Ontario | Canada |
| Research Site | Timmins | Ontario | Canada |
| Research Site | Toronto | Ontario | Canada |
| Research Site | Weston | Ontario | Canada |
| Research Site | Greenfield Park | Quebec | Canada |
| Research Site | Laval | Quebec | Canada |
| Research Site | Montreal | Quebec | Canada |
| Research Site | Québec | Quebec | Canada |
| Research Site | Ste-Foy | Quebec | Canada |
| Research Site | Saskatoon | Saskatchewan | Canada |
| 19211712 | Derived | Burgess E, Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S; SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol. 2009 Apr;20(4):893-900. doi: 10.1681/ASN.2008040416. Epub 2009 Feb 11. |
| ID | Term |
|---|---|
| D011507 | Proteinuria |
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D014555 | Urination Disorders |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C077793 | candesartan cilexetil |
Not provided
Not provided
Not provided